ThromboGenics says U.S. authorities clear its main drug

BRUSSELS (Reuters) - Belgian biotech company ThromboGenics said on Thursday that U.S. health regulators had approved the use of its main drug, eye treatment Jetrea.

via Reuters: Health News Read More Here..